Analysts Conflicted on These Industrial Goods Names: Flowserve (FLS), ALS (OtherCPBLF) and Graincorp Limited Class A (OtherGRCLF)
Companies in the Industrial Goods sector have received a lot of coverage today as analysts weigh in on Flowserve (FLS – Research Report), ALS (CPBLF – Research Report) and Graincorp Limited Class A (GRCLF – Research Report).
Confident Investing Starts Here:
Flowserve (FLS)
In a report issued on May 15, Deane Dray from RBC Capital maintained a Buy rating on Flowserve, with a price target of $59.00. The company's shares closed last Monday at $51.37.
According to TipRanks.com, Dray is a 5-star analyst with an average return of 13.6% and a 64.3% success rate. Dray covers the Industrial Goods sector, focusing on stocks such as Atkore International Group, Emerson Electric Company, and Honeywell International.
Currently, the analyst consensus on Flowserve is a Strong Buy with an average price target of $61.00, a 20.6% upside from current levels. In a report issued on April 30, TD Cowen also maintained a Buy rating on the stock with a $75.00 price target.
ALS (CPBLF)
RBC Capital analyst Nicholas Daish maintained a Hold rating on ALS on May 15 and set a price target of A$17.50. The company's shares closed last Thursday at $9.53.
According to TipRanks.com, Daish is ranked #3877 out of 9558 analysts.
Currently, the analyst consensus on ALS is a Strong Buy with an average price target of $11.17.
Graincorp Limited Class A (GRCLF)
In a report issued on May 15, Owen Birrell from RBC Capital maintained a Buy rating on Graincorp Limited Class A, with a price target of A$9.75. The company's shares closed last Monday at $4.86.
According to TipRanks.com, Birrell is a 2-star analyst with an average return of 0.7% and a 44.0% success rate. Birrell covers the Industrial Goods sector, focusing on stocks such as Auckland International Airport, Cleanaway Waste Management, and Qantas Airways Limited.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Graincorp Limited Class A with a $5.63 average price target, a 15.8% upside from current levels. In a report issued on May 16, Ord Minnett also maintained a Buy rating on the stock with a A$9.75 price target.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 hours ago
- Yahoo
Industrial tech firms Chart Industries, Flowserve set for all-stock merger
-- Industrial-process technology firms Chart Industries Inc (NYSE:GTLS) and Flowserve Corporation (NYSE:FLS), are on the brink of finalizing an all-stock merger, according to a Wall Street Journal report on Wednesday. The combined entity would be worth roughly $19 billion, including debt, the report said, citing people familiar with the matter. Shares of Chart Industries fell about 2% in pre-market trading, while Flowserve gained over 1%. Under the terms of the merger, Chart Industries shareholders will receive 3.165 shares of Flowserve common stock for every share of Chart common stock they own, the report added. After the completion of the transaction, Chart Industries shareholders will own a majority stake of 53.5% in the combined entity, with Flowserve shareholders holding the remaining 46.5%, according to the Journal. The deal, which is expected to be announced as early as Wednesday. Related articles Industrial tech firms Chart Industries, Flowserve set for all-stock merger UBS upgrades Snowflake on signs of sustained data infrastructure investment Any near-term weakness in S&P 500 would provide a 'buy the dip' opportunity: JPM Sign in to access your portfolio
Yahoo
6 hours ago
- Yahoo
Morning Movers: Chart Industries, Flowserve both rise following merger pact
Stock market futures are slightly lower this morning as investors digest a mix of tariff and jobs concerns. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Traders are focused on the labor market this week, with jobless claims and the May employment report on the horizon. After ADP announced private payrolls increased a lean 37,000 in May, President Trump repeated his view that the Fed 'must' lower rates 'now.' Meanwhile, concern about the impact of tariffs have been stoked again following a warning from Dollar Tree about profit pressure related to import costs. Oil prices are steady as Canadian wildfire risks appear to be easing slightly, helping calm supply fears. In crypto, Uniswap's token has surged above $6.75 on signs of accumulation by larger investors, with some analysts pointing to a shift in market sentiment. In pre-market trading, S&P 500 futures fell 0.03%, Nasdaq futures fell 0.04% and Dow futures fell 0.06%. Check out this morning's top movers from around Wall Street, compiled by The Fly. HIGHER – Chart Industries (GTLS) and Flowserve (FLS) up 6% and 4%, respectively, after announcing that they have entered into a definitive agreement to combine in an all-stock merger of equals UP AFTER EARNINGS – Guidewire (GWRE) up 13% REV Group (REVG) up 10% Genesco (GCO) up 9% Thor Industries (THO) up 8% Sprinklr (CXM) up 2% HP Enterprise (HPE) up 6% HealthEquity (HQY) up 4% DOWN AFTER EARNINGS – Sportman's Warehouse (SPWH) down 4% Dollar Tree (DLTR) down 2% CrowdStrike (CRWD) down 7% Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders' Hot Stocks on TipRanks >> Read More on GTLS: Disclaimer & DisclosureReport an Issue Chart Industries and Flowserve Announce Merger Agreement Chart Industries, Flowserve say agreement to generate $300M of annual synergies Chart Industries, Flowserve to combine in all-stock merger of equals Chart Industries, Flowserve near all-stock deal worth about $19B, WSJ reports Chart Industries shares up 5% premarket following WSJ report
Yahoo
9 hours ago
- Yahoo
Corcept Presents Results from Phase 2 Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis (ALS) at ENCALS 2025 Annual Meeting
DAZALS did not meet its primary endpoint of improved outcome in the ALS Functional Rating Scale-Revised (ALSFRS-R) in patients who received dazucorilant compared to patients who received placebo DAZALS met its secondary endpoint of improved overall survival at week 24 of the study in patients who received 300 mg of dazucorilant compared to patients who received placebo Exploratory analysis at the one-year mark shows continued significant improvement in overall survival between patients who received 300 mg of dazucorilant and those who received placebo only Corcept seeking guidance from United States and European regulators on optimum path forward REDWOOD CITY, Calif., June 05, 2025--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, presented results from its DAZALS study of dazucorilant in patients with ALS at the European Network to Cure ALS (ENCALS) 2025 annual meeting. The presentation can be found here. DAZALS is a randomized, double-blind, placebo-controlled Phase 2 study in which 249 patients with ALS were randomized to receive either 150 mg of dazucorilant, 300 mg of dazucorilant or placebo, daily for 24 weeks. Patients who completed the treatment period were eligible to enroll in a long-term extension study in which all patients received 300 mg of dazucorilant. The primary endpoint in DAZALS was the difference in ALSFRS-R between patients who received dazucorilant and those who received placebo. Overall survival was a secondary endpoint. Although DAZALS did not meet its primary endpoint, patient survival significantly improved. At week 24 of the study, no deaths had occurred in the 83 patients who received 300 mg of dazucorilant, while there were five deaths in the 82-patient placebo group (p-value of 0.02). An exploratory analysis conducted at the one-year mark shows the survival benefit has continued. Patients randomized to 300 mg of dazucorilant lived significantly longer than patients who received placebo and did not switch to 300 mg of dazucorilant in the extension study. The difference between groups was pronounced, with a hazard ratio of 0.16 (p-value: 0.0009). See Figure 1. A similar survival benefit was observed in patients who received 300 mg of dazucorilant for greater than 24 weeks, either in the treatment period or in the extension study, compared to patients who received either placebo or 150 mg of dazucorilant for 24 weeks and did not receive dazucorilant in the extension study (hazard ratio: 0.36; p-value 0.02). See Figure 2. The extension study is ongoing. Dazucorilant has demonstrated an acceptable safety profile, with 92 percent of adverse events being mild to moderate in severity. The frequency of severe and serious adverse events in patients who received dazucorilant was similar to those who received placebo. Mild to moderate, dose-related, transient abdominal pain was the most common adverse effect. "The improvement in overall survival, first noted in the DAZALS study at six months, continues to be seen at one-year. This finding deserves our full attention in service to patients with this tragic disease. Progress in the development of new ALS treatments is of critical importance," said Leonard H. van den Berg, M.D., Ph.D., Professor and Chair in the Department of Neurology, UMC Utrecht Brain Centre, Utrecht, The Netherlands, and Principal Investigator in the DAZALS study. "Medications that can extend life for patients with ALS are urgently needed. We are working with regulatory authorities to determine the optimal path for advancing dazucorilant," said Bill Guyer, PharmD, Corcept's Chief Development Officer. "We would like to thank the patients, their families and care partners, as well as the investigators, doctors and clinic staff involved in this study." About the DAZALS Study DAZALS is a randomized, double-blind, placebo-controlled Phases 2 trial in which 249 patients with ALS were randomized 1:1:1 to receive either 150 mg of dazucorilant, 300 mg of dazucorilant or placebo daily for 24 weeks. Patients who completed the treatment period were eligible to enroll in the long-term extension study in which all patients received 300 mg of dazucorilant. Baseline patient characteristics, including the ENCALS risk score, time from diagnosis, ALSFRS-R total score, and bulbar onset, were consistent across study arms. The DAZALS primary endpoint was the difference in change from baseline during the study's 24-week treatment period in ALSFRS-R score between patients who received dazucorilant and those who received placebo. Key secondary endpoints include overall survival and quality of life. DAZALS was conducted at sites in Europe, the United States and Canada. About Amyotrophic Lateral Sclerosis (ALS) ALS, also known as Lou Gehrig's disease or motor neuron disease, is a fatal degenerative neurologic disorder that affects more than 55,000 people in the United States and Europe. ALS causes muscles to weaken and, as the disease progresses, severely impairs patients' ability to speak, eat, move and breathe. There is increasing evidence that patients with ALS, particularly those with rapid disease progression, exhibit elevated or abnormal cortisol levels. A patient's life expectancy after diagnosis is two to five years. About Dazucorilant Dazucorilant is a selective cortisol modulator that binds to the glucocorticoid receptor but does not bind to the body's other hormone receptors. Corcept is studying it as a potential treatment for ALS and other neurologic disorders. Dazucorilant is proprietary to Corcept and is protected by composition of matter, method of use and other patents. The U.S. Food and Drug Administration has granted dazucorilant Fast Track Designation and orphan drug status for the treatment of ALS in the United States. About Corcept Therapeutics For over 25 years, Corcept has focused on cortisol modulation and its potential to treat patients with a wide variety of serious disorders and has discovered more than 1,000 proprietary selective cortisol modulators and glucocorticoid receptor antagonists. Corcept is conducting advanced clinical trials in patients with hypercortisolism, solid tumors, ALS and liver disease. In February 2012, the company introduced Korlym®, the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with endogenous hypercortisolism. Corcept is headquartered in Redwood City, California. For more information, visit Forward-Looking Statements Statements in this press release, other than statements of historical fact, are forward-looking statements based on our current plans and expectations, which are subject to risks and uncertainties that might cause our actual results to differ materially from those such statements express or imply. These risks and uncertainties are set forth in our SEC filings, which are available at our website and the SEC's website. In this press release, forward-looking statements include those concerning the development of dazucorilant as a treatment for patients with ALS, including the pace, conduct, timing and outcome of DAZALS and its associated long-term extension study, as well as oversight or requirements that may be imposed by the FDA or other regulatory authorities. We disclaim any intention or duty to update forward-looking statements made in this press release. View source version on Contacts Investor inquiries:ir@ Media inquiries:communications@
